History
  • No items yet
midpage
287 F.R.D. 357
D. Maryland
2012
Read the full case

Background

  • Aredia and Zometa are FDA-approved drugs sold by Novartis; court previously granted punitive damages preclusion.
  • Plaintiff Phyllis Newman pursued strict liability and negligence claims in Maryland-related litigation arising from ONJ after using Aredia/Zometa for cancer treatment.
  • Case posture moved from MDL proceedings to this court; remanded for trial with pending summary-judgment motions.
  • Newman died in 2007; Stacy Zimmerman, as personal representative, continued the action against Novartis in 2007 in the Middle District of Tennessee before transfer/remand.
  • Plaintiff abandoned the “drug holiday” causation theory and advanced two new proximate-causation theories regarding prior extraction and physician knowledge.
  • Court grants Novartis’s renewed motion for summary judgment on proximate causation, citing lack of evidence that warnings would have altered Ms. Newman’s treatment and that tooth #16’s extraction was medically required regardless of warnings.

Issues

Issue Plaintiff's Argument Defendant's Argument Held
Proximate causation for failure to warn in drug-induced ONJ Plaintiff argues warnings could have changed dental decisions pre- or post-ONJ onset Warning would not have prevented extraction decisions; causation cannot be shown Proximate causation not proven; summary judgment for Novartis granted
Post-hearing affidavits and discovery requests compatibility with summary judgment New expert affidavit creates genuine dispute; discovery needed Affidavit contradicts deposition and is insufficient; discovery not warranted Sham affidavit doctrine applied; additional discovery denied
Rule 56(d) discovery standards applicability Rule 56(d) permit discovery to obtain necessary facts Discovery sought was untimely; available earlier; not showable as needed Rule 56(d) motion denied; no need for further discovery

Key Cases Cited

  • Celotex Corp. v. Catrett, 477 U.S. 317 (1986) (summary judgment standard; burden shifting)
  • Anderson v. Liberty Lobby, Inc., 477 U.S. 242 (1986) (material facts must be viewed in the light most favorable to the nonmoving party)
  • Ames v. Apothecon, Inc., 431 F.Supp.2d 566 (D.Md.2006) (causation in failure-to-warn cases)
  • Beale v. Hardy, 769 F.2d 213 (4th Cir.1985) (genuine issue of material fact standard)
  • Bouchat v. Baltimore Ravens Football Club, Inc., 346 F.3d 514 (4th Cir.2003) (summary judgment burden on opposing party)
Read the full case

Case Details

Case Name: Zimmerman v. Novartis Pharmaceuticals Corp.
Court Name: District Court, D. Maryland
Date Published: Nov 16, 2012
Citations: 287 F.R.D. 357; 84 Fed. R. Serv. 3d 410; 2012 U.S. Dist. LEXIS 163865; 2012 WL 5816873; No. RWT 08cv2089
Docket Number: No. RWT 08cv2089
Court Abbreviation: D. Maryland
Log In
    Zimmerman v. Novartis Pharmaceuticals Corp., 287 F.R.D. 357